Thuja Capital

Thuja Capital Management B.V. is a venture capital and private equity firm based in Utrecht, Netherlands, focused on early-stage investments in the healthcare sector. Established in 2006, the firm specializes in seed and start-up financing, primarily targeting innovations in medical devices, diagnostics, therapeutics, digital health, and nutraceuticals. Thuja Capital emphasizes investments in the Benelux region, including the Netherlands, Belgium, and Luxembourg, and typically commits between €0.25 million and €2.5 million in equity, as well as between €0.50 million and €1 million in debt. The firm prefers to take an active role by securing a seat on the supervisory board of its portfolio companies. Through its strategic investments, Thuja Capital aims to support the development of pioneering medical products and technologies that contribute to diagnosis, treatment, and prevention in healthcare.

Michel Briejer

Managing Partner

Evan Castiglia

Investment Director and Partner

Tyler Hayes MD

Principal

Past deals in Rotterdam

arGEN-X

Series A in 2010
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.